Learn what GDocP and GDP covers, why they matter for compliance, and how QA teams apply the practices.
In the pharmaceutical industry, GDP can stand for two related disciplines. Good Documentation Practice, often shortened to GDocP, is the GxP discipline governing how pharmaceutical records are created, corrected, reviewed, and retained. Good Distribution Practice is the set of standards governing how medicines are stored, transported, and handled once they leave the manufacturer.
Both answer the same question for a regulator: can you prove, with evidence, that a medicine is what it claims to be? Documentation carries most of that weight. Good Manufacturing Practice (GMP), Good Clinical Practice (GCP), and Good Laboratory Practice (GLP) cannot be achieved without strictly following Good Documentation Practice, because an inspector can only assess what has been recorded. If it is not documented, it did not happen.
This article covers both. To keep the terms distinct, it uses GDocP for Good Documentation Practice and GDP for Good Distribution Practice. The first part explains where GDocP requirements come from, the ALCOA+ principles behind them, who is responsible and what happens when compliance fails. The second part explains what Good Distribution Practice covers, its key principles and who needs to comply.
GDocP sits within the broader GxP framework alongside Good Manufacturing Practice (GMP), Good Laboratory Practice (GLP), Good Clinical Practice (GCP), and Good Pharmacovigilance Practice (GVP). Each of these disciplines depends on reliable records, so documentation requirements appear in all of them.
There is no single standalone “GDocP regulation.” Instead, documentation expectations are woven through quality-system requirements and data integrity guidance issued by each regulator. The most frequently referenced sources include:
For QA and regulatory teams, the practical consequence is that GDocP is not defined in one place and does not stand still. Expectations are interpreted through inspections and refreshed through new guidance, so internal SOPs need regular review against the current texts.
ALCOA+ is the operational backbone of Good Documentation Practice. The original ALCOA acronym describes five attributes that every record should have: attributable, legible, contemporaneous, original, and accurate. The “plus” adds four more: complete, consistent, enduring, and available. The FDA, the MHRA, PIC/S, and WHO all reference these attributes in their data integrity guidance, and they apply equally to paper and electronic records. Some newer guidance, including the EU’s draft revision of Chapter 4, extends the set further to ALCOA++ by adding traceability.
The table below sets out what each GDocP principle means in practice.
On the shop floor and in the laboratory, these principles translate into a small set of everyday habits: record in permanent ink, never in pencil or on scrap paper; correct errors with a single line so the original remains readable, then initial, date and give a reason; never use correction fluid or overwrite; line through unused spaces so nothing can be added later; and review audit trails as part of routine record review, not only before an inspection.
Good Documentation Practice is not an administrative overhead. It is the evidence base that every quality and regulatory decision rests on. Its importance comes down to five areas:
Everyone who creates, reviews, or approves a GxP record shares responsibility for its quality, and senior management is accountable for providing the systems, training, and resources that make compliance possible. Within that, four groups carry specific responsibilities:
Most GDocP failures are not deliberate. They come from systems and habits that make good practice harder than it should be. The most common challenges are:
These gaps tend to surface at the worst possible moment. Building inspection readiness into routine operations, rather than treating it as a pre-inspection exercise, is the most reliable way to find and close them early.
The consequences escalate. The FDA Form 483 observations and warning letters citing data integrity or documentation failures are among the most common inspection findings, and consequences can escalate to import alerts and product recalls.
A typical escalation path looks like this:
European and UK regulators have comparable tools, including GMP non-compliance statements and the suspension of manufacturing or wholesale authorizations. The pattern of findings across the industry is also a useful signal: the documentation failures cited at other sites today are often the questions your inspectors will ask tomorrow.
Infodesk’s Inspection and Enforcement Intelligence helps your team track these enforcement patterns across agencies and reduce the time spent preparing for inspections, so you can address emerging issues before they appear in your own findings.
Good Distribution Practice is the set of quality standards ensuring medicines are stored, transported, and handled correctly throughout the supply chain, from manufacturer to pharmacy. Its purpose is to make sure the quality established at manufacture is maintained until the product reaches the patient, and that falsified medicines do not enter the legal supply chain.
GDP applies to wholesale distributors, not only logistics providers, and covers the full chain of custody. In the EU, it is legally mandated under the Guidelines on Good Distribution Practice of medicinal products for human use (2013/C 343/01). WHO publishes equivalent guidance on good storage and distribution practices that is used globally, and in the UK, GDP is enforced by the MHRA.
GDP is built on a small number of principles that together protect product quality from the moment a medicine leaves the manufacturer. The table below summarizes what each one covers.
Documentation and traceability is where GDP and GDocP meet: temperature logs, handover records and deviation reports in the supply chain are held to the same ALCOA+ principles as batch records in manufacturing.
GDP obligations follow the product, not the type of company. Any organization that procures, holds, supplies, or exports medicines as part of distribution needs to comply, including:
Where activities are outsourced, responsibility is not. The authorization holder remains accountable for making sure subcontracted storage and transport meet GDP requirements.
GDocP and GDP expectations are set by many regulators, on different timelines, and they continue to evolve. For QA and regulatory teams, the challenge is not only meeting today’s requirements but knowing when they change. Learn more about how Infodesk supports quality assurance and GxP teams.
Infodesk supports end-to-end GDocP and GDP compliance with intelligence activation across three solutions which reflect the surveillance to action steps of the QA workflow:
Infodesk’s regulatory intelligence platform is the surveillance layer that keeps QA and regulatory teams ahead of evolving documentation and data integrity guidance from the FDA, the EMA, MHRA, PIC/S, and WHO.
Infodesk’s Inspection & Enforcement Intelligence solution gives you a database of the inspector’s history, your site’s full record, and the findings escalating right now. Inspection and Enforcement Intelligence (I&E Intelligence) pulls every inspection record and enforcement action into one place across seven health authorities, then turns it into the profiles, briefs, and reports your team needs to prepare. This way inspection findings from elsewhere in the industry become early-warning signals rather than surprises and you can always be inspection-ready.
Infodesk’s Workflow Solution ensures curated, validated intelligence is delivered directly into your workflows, so impact assessments can be easily managed and SOPs and training stay current.
Infodesk gives you the clarity, confidence and proof to act, when action matters most. To see how Infodesk can support your GDocP and GDP programs, book a meeting with our team.
Share this article